Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C, Li H, Yang X, Wang S, Wang Y, Zhang N, Wang Y, Xue J, Zhang L, Ning C, Yang X, Xun Z, Chao J, Long J, Sang X, Zhu Z, Zhao H. Zhu C, et al. Among authors: zhang n, zhang l. Cancer Immunol Immunother. 2023 Sep;72(9):2949-2960. doi: 10.1007/s00262-023-03466-8. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37247023 Free PMC article.
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Chao J, Wang S, Wang H, Zhang N, Wang Y, Yang X, Zhu C, Ning C, Zhang X, Xue J, Zhang L, Piao M, Wang M, Yang X, Lu L, Zhao H. Chao J, et al. Among authors: zhang n, zhang l, zhang x. Cancer Immunol Immunother. 2023 Nov;72(11):3717-3726. doi: 10.1007/s00262-023-03523-2. Epub 2023 Oct 3. Cancer Immunol Immunother. 2023. PMID: 37787790 Free PMC article.
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Wang S, Wang Y, Zhu C, Liu K, Chao J, Zhang N, Piao M, Yang X, Zhang L, Long J, Xun Z, Zhang T, Sang X, Yang X, Zhao H. Wang S, et al. Among authors: zhang n, zhang l, zhang t. Int J Surg. 2024 Aug 1;110(8):4608-4616. doi: 10.1097/JS9.0000000000001540. Int J Surg. 2024. PMID: 38704621 Free PMC article.
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer.
Zhu C, Wang Y, Zhu R, Wang S, Xue J, Zhang D, Lan Z, Zhang C, Liang Y, Zhang N, Xun Z, Zhang L, Ning C, Yang X, Chao J, Long J, Yang X, Wang H, Sang X, Jiang X, Zhao H. Zhu C, et al. Among authors: zhang n, zhang l, zhang c, zhang d. Biomark Res. 2024 Jun 3;12(1):56. doi: 10.1186/s40364-024-00607-8. Biomark Res. 2024. PMID: 38831368 Free PMC article.
Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
Tan Y, Liu K, Zhu C, Wang S, Wang Y, Xue J, Ning C, Zhang N, Chao J, Zhang L, Long J, Yang X, Zeng D, Zhao L, Zhao H. Tan Y, et al. Among authors: zhang n, zhang l. Cancer Immunol Immunother. 2024 Oct 3;73(12):240. doi: 10.1007/s00262-024-03831-1. Cancer Immunol Immunother. 2024. PMID: 39358463 Free PMC article.
19,295 results
You have reached the last available page of results. Please see the User Guide for more information.